We recently compiled a list of the Top 12 Stocks to Buy According to Bourgeon Capital. In this article, we are going to take ...

Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...

The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 ...

If Axsome doesn’t, Teva can enter the U.S. market with its copy on Sept. 30, 2038. Auvelity is one of three drugs Axsome sells and by far the company’s top product. Auvelity combines a form of ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

Teva Pharmaceutical is one of the ... enjoy commercial success in the field. New products, including Ajovy, Austedo, and Uzedy, will fuel Teva's top and bottom lines as their adoption increases.

Teva Pharmaceutical Industries Ltd. (NYSE ... driven by our generic products and key innovative products. Medicine Pills (credit: INGIMAGE) Focusing on the rigorous execution of our Pivot to ...

covering some of the most notable news stories of the time. SOPA Images / Contributor / Getty Images Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration ...

In October 2024, the FDA approved the biosimilar SELARSDI™ (ustekinumab-aekn), manufactured by Teva Pharmaceuticals ... commercialize additional pharmaceutical products; our ability to ...

The U.S. Food and Drug Administration (FDA) has approved SELARSDI™ (ustekinumab-aekn), a biosimilar to Stelara® (ustekinumab), for treating various conditions including plaque psoriasis ...